Effect of three B-cell inhibitors: rituximab, alemtuzumab and bortezomib on anti-A and/or anti-B titer kinetics.

Effect of three B-cell inhibitors: rituximab, alemtuzumab and bortezomib on anti-A and/or anti-B titer kinetics. - anti-A/B titers

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39959

Enrollment

Registered

2013-02-19

Start date

2013-02-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidneytransplant

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: age * 18 yr patients should be competent have blood group A,B or O will receive treatment with rituximab, bortezomib, alemtuzumab (prescribed by their hematologist)

Exclusion criteria

Exclusion criteria: blood group AB having a low antiA/B titer

Design outcomes

Primary

Measure	Time frame
The dynamics of the anti A/B titer in time of three different B cell-inhibitors (rituximab, bortezomib, alemtuzumab).	—

Secondary

Measure	Time frame
effect of blood transfusions on the anti A?B titers.	—

Countries

Netherlands

Outcome results